Starget Pharma, a biotech startup that leverages targeted radiotherapy for diagnostic and targeted cancer treatment, has raised $5.1 million from Cancer Focus to advance treatments for metastatic cancer to clinical trials.
Co-founded in 2019 by a multi-disciplinary team comprising experts in peptide-based drug discovery and business entrepreneurs, the company focuses on developing Smart Targeted Radioligands critical for precision oncology.
The new investment will support the company’s efforts in advancing new therapies to clinical trials to test their efficacy in treating various types of metastatic cancers, including melanoma, sarcomas, liver cancer, and neuroendocrine tumors.
Leveraging the Power of AI for Personalized Cancer Care
Stargate Pharma’s platform combines advanced diagnostic imaging capabilities with targeted radiotherapy to create an individualized treatment that helps improve therapy outcomes for patients with late-stage cancers.
It allows for precise delivery of radiation to targeted tumor cells and minimizes damage to the surrounding healthy tissues. Additionally, the platform allows doctors to select the most suitable treatment plans based on tumor characteristics as well as patient needs.
According to Sigal Clemenson-Kushnir, CEO of Starget Pharma, the company’s new technology offers a viable alternative to the limited therapy options available for patients with advanced cancer stages.
The upcoming clinical will be undertaken in 2025 at the University of Texas MD Anderson Cancer Center.
